Table 3 Changes of the risk of hip fracture
From: Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients
FRAX | Treatment 1 (n = 18) | p* | Treatment 2 (n = 20) | p* | Control (n = 18) | p* |
|---|---|---|---|---|---|---|
Before treatment | 5.76 ± 1.45 | – | 5.86 ± 1.59 | – | 5.83 ± 1.74 | – |
6 months | 5.08 ± 2.17 | 0.047 | 5.98 ± 2.73 | 0.097 | 5.65 ± 1.67 | 0.145 |
12 months | 4.34 ± 1.78△ | 0.035 | 5.44 ± 1.89△ | 0.072 | 5.64 ± 2.09 | 0.139 |